Yatharth Hospital Q4 FY26: Standalone sales up 46% YoY

Key takeaway from the March 2026 quarter

Yatharth Hospital and Trauma Care Services Ltd. reported strong year-on-year growth in its March 2026 quarter, led by a sharp rise in revenue on both standalone and consolidated bases. The standalone print showed higher sales and EBITDA versus the year-ago quarter, while profit growth was more moderate. The company also reported a lower standalone EPS compared with the March 2025 quarter.

On the consolidated side, Yatharth Hospital posted a bigger jump in revenue and profits than the standalone business, reflecting the wider group performance. The updates were accompanied by published quarterly line items such as expenditure, operating profit, interest, depreciation and tax for the standalone results.

Standalone Q4 FY26: revenue rises to ₹163.87 crore

Standalone net sales for the quarter ended March 2026 came in at ₹163.87 crore, up 46.32% from ₹111.99 crore in March 2025. The same ₹163.87 crore figure is also shown as total income from operations for the quarter.

EBITDA for the standalone business stood at ₹45.94 crore in March 2026, up 28.04% from ₹35.88 crore in March 2025. Despite the revenue expansion, standalone net profit increased at a slower pace. Quarterly net profit was reported at ₹23.76 crore, up 8.49% from ₹21.90 crore in the year-ago quarter.

Standalone EPS for Yatharth Hospital decreased to ₹2.47 in March 2026 from ₹2.55 in March 2025, as per the reported numbers.

What the quarterly P&L lines show

A detailed quarterly table (all figures in ₹ crore) shows total expenditure rising to ₹124.69 crore in March 2026 from ₹80.22 crore in March 2025. Operating profit in March 2026 was reported at ₹39.18 crore versus ₹32.29 crore in March 2025.

Other income was reported at ₹6.76 crore in March 2026, higher than ₹3.58 crore in March 2025. A notable line item in March 2026 was interest cost at ₹4.48 crore, compared with ₹0.15 crore in March 2025, alongside higher depreciation of ₹10.45 crore versus ₹4.71 crore a year earlier.

Profit before tax (PBT) was shown at ₹31.01 crore in March 2026 and tax at ₹7.26 crore.

Quarterly trend through FY26 (standalone)

The standalone quarterly data across FY26 shows a steady rise in revenue through the year. Net sales increased from ₹112.51 crore in March 2025 to ₹130.14 crore (June 2025), ₹137.29 crore (September 2025), ₹158.15 crore (December 2025) and ₹163.87 crore (March 2026).

Over the same period, operating profit moved from ₹32.29 crore (March 2025) to ₹35.05 crore (June 2025), dipped to ₹26.95 crore (September 2025), then rose to ₹36.55 crore (December 2025) and ₹39.18 crore (March 2026). Interest cost stayed low through most of the year but increased sharply to ₹4.48 crore in March 2026.

Consolidated Q4 FY26: sales up 47% and profit up 23%

On a consolidated basis, Yatharth Hospital reported net sales of ₹341.56 crore in March 2026, up 47.36% from ₹231.78 crore in March 2025. Consolidated net profit rose 22.73% to ₹47.52 crore from ₹38.72 crore in the year-ago quarter.

Consolidated EBITDA was reported at ₹87.02 crore in March 2026, up 39.52% from ₹62.37 crore in March 2025. The report also indicated consolidated EPS increased to ₹4.93 in March 2026.

FY26 consolidated numbers: revenue crosses ₹1,200 crore

For the year ended March 2026, consolidated sales were reported at ₹1,207.17 crore compared with ₹880.49 crore in the year ended March 2025, a rise of 37.10%. Annual consolidated net profit (NP) was shown at ₹175.38 crore for FY26 versus ₹130.55 crore for FY25.

Additional annual metrics presented include PBDT of ₹311.37 crore (FY26) versus ₹228.85 crore (FY25), and PBT of ₹223.56 crore (FY26) versus ₹171.74 crore (FY25). Operating margin (OPM %) was listed at 24.20% for FY26 and 25.01% for FY25.

Share price reference points reported

The reported update noted Yatharth HOSP shares closed at ₹816.35 on May 25, 2026 (NSE). A separate line in the provided information also mentioned the stock closed at ₹820.55 on May 22, 2026 (NSE).

Snapshot table: key reported figures

Market impact and what investors typically watch in these numbers

The reported quarter combines rapid revenue growth with a slower rise in standalone profit, alongside an EPS decline year-on-year on the standalone basis. The quarterly cost lines also show a higher depreciation charge and a significantly higher interest cost in March 2026 compared with the March 2025 quarter in the standalone table.

For investors, the separation between standalone and consolidated performance matters because the consolidated results capture group-level earnings and profitability. The data also provides a quarterly run-rate view of sales scaling through FY26, with net sales rising from ₹112.51 crore in March 2025 to ₹163.87 crore by March 2026 on a standalone basis.

Why the update matters

Yatharth Hospital’s reported results point to a period of expansion in the top line, with consolidated revenue growth also translating into stronger consolidated profit growth. At the same time, the standalone table highlights changes in financing and non-cash costs in the March 2026 quarter through the jump in interest and higher depreciation.

The next market focus typically shifts to subsequent quarterly filings and any additional company commentary that may accompany future result releases. The latest reference points provided place the stock around ₹816-821 on the NSE in late May 2026.